The European Medicines Agency has solidified its recommendations to drugmakers that want to use single-arm designs in a ...
The FDA on Monday released new draft guidance on conducting multi-regional oncology trials, saying its ...
Eli Lilly's drug lebrikizumab has been approved for the treatment of eczema, or atopic dermatitis, a win for the company ...
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as ...
Summit and Akeso set the industry abuzz after their bispecific antibody beat Merck’s Keytruda in a Phase 3 lung cancer trial. Now, BioNTech is touting mid-stage data for its own lung cancer asset with ...
Immatics presented more clinical data on its bispecific T cell engager at Europe's largest cancer conference. But the German and US biotech is losing its partner on the Phase 1 drug, which became one ...
In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese's candy, call himself an 'old fart' when asked about career plans, get real about the ...
A new treatment option for a wide range of patients diagnosed with neuroendocrine tumors could be approved in April, as final ...
Three clinical-stage biotechs, three upsized offerings and three first-day share spikes. Last Friday's biotech IPO ...
The mRNA-based Covid vaccines used by hundreds of millions of people may provide an unexpected benefit to some cancer ...
Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback